NEW YORK, Oct. 3, 2018 /PRNewswire/ — Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis, today announced the issuance of a Priority Health of Michigan Medical Policy. The policy, effective August 20 2018, now includes coverage of the coflex® Interlaminar Stabilization® device for lumbar spinal stenosis with no prior authorization required. This issuance adds to the continual growminimally invasive neck surgeryth of positive commercial payor policies for coflex®.
Lumbar spinal stenosis (“LSS”), affecting 1.6 million patients annually, is a debilitating and degenerative disease in older patients (>50 years) often associated with significant leg and back pain, leg numbness and weakness, causing a significant reduction in an active lifestyle. Traditional surgical treatment options for LSS includes a decompression that removes bone and soft tissue and may also require a fusion to stabilize the spine. The coflex® device is a non-fusion, motion-preserving stabilization implant, that is FDA PMA-approved for the treatment of lumbar spinal stenosis and is used in conjunction with a decompression, or used in lieu of a spinal fusion.
Marc Viscogliosi, Chairman & CEO of Paradigm Spine, said, “This coverage policy by Priority Health of Michigan reflects the continued adoption and understanding of the benefits coflex® offers patients with lumbar spinal stenosis. We look forward to expanding patient access to the coflex® technology to the more than 7spinal inc86,000 lives covered by Priority Health of Michigan – Michigan’s second largest health plan that is nationally recognized for improving the health and lives of the people it serves by providing quality care that’s accessible and affordable.”
To learn more about coflex® Interlaminar Stabilization®, please visit www.coflexspinal incsolution.com.
About Paradigm Spine, LLC
Paradigm Spine, LLC, founded in 2004, is a privately held company and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company’s signature product is the coflex® Interlaminar Stabilization® device, which is currently used in over 60 countries worldwide. coflex® is the only lumbar spinal device that has produced Level I evidence in two separate prospective, randomized, controlled studies against two different control groups, changing the standard of care for lumbar spinal stenosis treatment. For additional information visit www.paradigmspine.com or www.coflexsolution.com.
SOURCE Paradigm Spine, LLC